Juncture Wealth Strategies LLC cut its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 8.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,227 shares of the company’s stock after selling 2,273 shares during the quarter. Juncture Wealth Strategies LLC’s holdings in Omnicell were worth $1,224,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of OMCL. BlackRock Inc. increased its holdings in shares of Omnicell by 2.3% during the 2nd quarter. BlackRock Inc. now owns 4,589,119 shares of the company’s stock valued at $197,790,000 after purchasing an additional 101,776 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Omnicell by 3.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,928,201 shares of the company’s stock valued at $83,105,000 after purchasing an additional 67,902 shares in the last quarter. Conestoga Capital Advisors LLC increased its holdings in shares of Omnicell by 0.7% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,617,706 shares of the company’s stock valued at $82,584,000 after purchasing an additional 11,105 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Omnicell by 129.6% during the 2nd quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock valued at $53,096,000 after purchasing an additional 695,334 shares in the last quarter. Finally, Eagle Asset Management Inc. increased its holdings in shares of Omnicell by 14.7% during the 3rd quarter. Eagle Asset Management Inc. now owns 998,107 shares of the company’s stock valued at $52,200,000 after purchasing an additional 127,873 shares in the last quarter. 99.69% of the stock is owned by institutional investors.

In other Omnicell news, CFO Peter J. Kuipers sold 1,926 shares of Omnicell stock in a transaction on Monday, December 18th. The shares were sold at an average price of $51.69, for a total transaction of $99,554.94. Following the sale, the chief financial officer now owns 40,544 shares of the company’s stock, valued at approximately $2,095,719.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Peter J. Kuipers sold 4,724 shares of Omnicell stock in a transaction on Friday, November 17th. The stock was sold at an average price of $47.74, for a total transaction of $225,523.76. Following the sale, the vice president now directly owns 40,544 shares in the company, valued at approximately $1,935,570.56. The disclosure for this sale can be found here. Insiders sold a total of 27,558 shares of company stock worth $1,330,230 in the last three months. 3.77% of the stock is owned by corporate insiders.

Omnicell, Inc. (OMCL) traded up $1.15 during trading on Monday, reaching $51.70. 139,900 shares of the company were exchanged, compared to its average volume of 192,569. Omnicell, Inc. has a 1 year low of $32.70 and a 1 year high of $55.40. The firm has a market cap of $1,940.00, a PE ratio of -470.00, a P/E/G ratio of 4.10 and a beta of 0.71. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.38.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The firm had revenue of $186.78 million for the quarter, compared to analysts’ expectations of $192.45 million. During the same quarter last year, the company earned $0.40 EPS. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. sell-side analysts predict that Omnicell, Inc. will post 0.12 EPS for the current fiscal year.

OMCL has been the subject of several recent research reports. Oppenheimer reaffirmed a “buy” rating and set a $55.00 target price on shares of Omnicell in a report on Thursday, October 19th. Cantor Fitzgerald lifted their target price on shares of Omnicell to $58.00 and gave the company an “overweight” rating in a report on Friday, October 27th. Craig Hallum reaffirmed a “buy” rating and set a $62.00 target price (up from $52.00) on shares of Omnicell in a report on Monday, October 30th. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 1st. Finally, BidaskClub lowered shares of Omnicell from a “hold” rating to a “sell” rating in a report on Friday, December 22nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. Omnicell currently has a consensus rating of “Hold” and an average target price of $55.14.

COPYRIGHT VIOLATION WARNING: This story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://theolympiareport.com/2018/01/22/juncture-wealth-strategies-llc-sells-2273-shares-of-omnicell-inc-omcl.html.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.